Skip to main content
Uncategorized

An article by Cristian Obiol-Pardo from Intelligent Pharma, is the 5th most read in the Journal of Chemical Information and Modeling

By 25 de May de 2011November 18th, 2020No Comments
< Back to news
 25.05.2011

An article by Cristian Obiol-Pardo from Intelligent Pharma, is the 5th most read in the Journal of Chemical Information and Modeling

A project published in the Journal of Chemical Information and Modeling, in which scientist Cristian Obiol-Pardo computational chemist at the company –Intelligent Pharma– has participated, has been the 5th most frequently read article in this journal at a worldwide level during the first trimester of 2011. Intelligent Pharma is a biotech company, based at the Barcelona Science Park, dedicated to the development, commercialization and use of new computational technologies for the discovery of drugs, with the aim of supporting pharmaceutical and biotech companies in order to increase their efficiency in the design of new drugs.


In the article, titled “A multiscale simulation system for the prediction of drug-induced cardiotoxicity” (doi: 10.1021/ci100423z), the post-doctoral research conducted by Obiol-Pardo within the Computer Assisted Drug Design group (CADD) of the Biomedical Informatics Research Group (GRIB) (UPF-IMIM) is published. It also appeared on the cover of the February issue of the journal (February 28, 2011: Vol. 51, Iss. 2).

The work, developed by Cristian Obiol-Pardo, and other members of the team, makes a new system of multi-scale simulation accessible to the scientific community. This system is used to assess drug-induced cardiotoxicity and specifically to enable an improved pre-clinical prediction of the risk of suffering atrial arrhythmia secondary to the consumption of a certain medication.

The toxicity produced by certain drugs on vital organs such as the heart, liver or brain is one of the greatest obstacles in clinical trials. The multi-scale simulation system proposed by these researchers could be used in preliminary screenings of drugs in their early stages of development, spanning from the design phase to preclinical experimentation, helping to identify effective and safe drugs, preventing unnecessary risks, and confirming their safety in terms of cardiotoxicity much prior to their use during the clinical phase.